News Conference News HRS 2022 Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients Todd Neale April 29, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Daily News No Increased Bleeding With Alteplase in Stroke Patients on DOACs: Registry Data Yael L. Maxwell February 15, 2022
News Conference News ISC 2022 ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis Todd Neale February 10, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Daily News Shorter Anticoagulation an Option for Young Patients With Provoked VTE Todd Neale January 11, 2022
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Conference News AHA 2021 Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage Todd Neale November 19, 2021
News Conference News AHA 2021 GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients Todd Neale November 14, 2021
News Conference News TCT 2021 PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term Todd Neale November 05, 2021
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Daily News Long-term Anticoagulation After Unprovoked VTE: New Insights Shelley Wood September 13, 2021
News Conference News ESC 2021 Amulet IDE: LAA Occluder Performs Well Against Watchman Todd Neale August 30, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021